Hospital Universitario Lucus Augusti — Clinical Trial Site

125 Registered trials

47 Currently recruiting

Organisation

Hospital Universitario Lucus Augusti

Location

Lugo, Spain

Identifier

ORG-100042119

Address

Rua Dr. Ulises Romero 1, 27003, Spain

Departments

034031: Oncología Médica
2502:Oncología
Alergología
Alergology
Allergy
Anestesia
Cardiologia
CARDIOLOGY
Cirugía general
Departamento Urologia
Department of Urology
Digestivo
Enfermedades Infecciosas
Hematología
Hematology
Hematology and Hemotherapy
HU Lucus Augusti
infectious diseases
Lipids Unit
Medica Oncology
medical oncologist
Medical Oncology
Medical Oncology Department
N/A
Neurology Service
Oncologia
Oncología Médica
Oncology
Oncology Department
Oncology Service
Pneumology
Pneumology Service
Radiation Oncology
Respiratory Medicine
Reumatología
Servicio de digestivo
Servicio de Oncologia
Servicio de Oncologia Medica
Surgery
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
Urology

Clinical trials at this site (125)

Search interface

ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER. Recruiting

2024-519825-39-00 Locally advanced colon cancer (LACC) 4 2025-01-30
An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Recruiting

2024-512113-41-00 Severe Asthma 5 2024-11-20
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
N-PLUS Recruiting

2022-502559-69-01 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 201 4 2024-07-04
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted a… Recruiting

2023-508442-18-00 Patients with an infection of the osteosynthesis materi 5 2024-04-14
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/D… Ended

2024-518519-20-01 moderate/severe allergic rhinitis/rhinoconjunctivitis w 4 2025-04-10
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Study with Various Immunotherapy Treatments in Participants With Lung Cancer Ended

2022-502916-35-01 Advanced Non-Small Cell Lung Cancer 4 2024-03-27
Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adver… Ended

2023-505863-35-00 EGFR-mutated Advanced or Metastatic Non-small Cell Lung 4 2024-03-20
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera… Ended

2024-512573-27-01 Muscle-invasive bladder cancer (MIBC) 4 2023-12-11
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended

2023-504273-21-00 Multiple Myeloma 4 2023-10-31
Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsibl… Ended

2023-504434-22-00 Patients With EGFR-mutant Locally Advanced or Metastati 5 2023-10-03
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Study of chemotherapy and immunotherapy before and after surgery in patients with non-small cell lung cancer whose tumor is located in the u… Ended

2024-512359-19-00 Resectable Non-small cell lung cancer Pancoast tumor 4 2023-05-12
A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resist… Ended

2022-501139-17-01 Aggressive Variant Metastatic Castration Resistant Pros 4 2023-05-05
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23